Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors

[1]  C. V. van Asperen,et al.  Universal immunohistochemistry for Lynch Syndrome: a systematic review and meta-analysis of 58,580 colorectal carcinomas. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  G. Sauter,et al.  Mismatch repair deficiency occurs very rarely in seminomas , 2021, Translational andrology and urology.

[3]  F. Balaguer,et al.  Comprehensive Genomic Characterization of Fifteen Early-Onset Lynch-Like Syndrome Colorectal Cancers , 2021, Cancers.

[4]  A. Viari,et al.  Acquired somatic MMR deficiency is a major cause of MSI tumor in patients suspected for “Lynch-like syndrome” including young patients , 2020, European Journal of Human Genetics.

[5]  H. Morreau,et al.  Prevalence of mismatch repair deficiency and Lynch syndrome in a cohort of unselected small bowel adenocarcinomas , 2020, Journal of Clinical Pathology.

[6]  M. Salto‐Tellez,et al.  Identifying mismatch repair‐deficient colon cancer: near‐perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population‐based series , 2020, Histopathology.

[7]  F. Coulet,et al.  Molecular tumor testing in patients with Lynch-like syndrome reveals a de novo mosaic variant of a mismatch repair gene transmitted to offspring , 2020, European Journal of Human Genetics.

[8]  J. Cubiella,et al.  Clinical and Pathological Characterization of Lynch-Like Syndrome. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  A. Gonzalez-Perez,et al.  The mutational footprints of cancer therapies , 2019, bioRxiv.

[10]  Lik Hang Lee,et al.  Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade , 2019, Modern Pathology.

[11]  N. Ellis,et al.  Implication of DNA repair genes in Lynch-like syndrome , 2019, Familial Cancer.

[12]  K. Ness,et al.  Premature Aging in Young Cancer Survivors. , 2019, Journal of the National Cancer Institute.

[13]  Ahmet Zehir,et al.  Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Witjes,et al.  Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Berney,et al.  ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  N. Lawrentschuk,et al.  Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome , 2018, Bladder cancer.

[17]  R. Yantiss,et al.  Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing , 2018, Modern Pathology.

[18]  L. Adán-Merino,et al.  Diagnosis and clinical behavior in patients with Lynch-like syndrome. , 2018, Revista de gastroenterologia de Mexico.

[19]  N. LeBrasseur,et al.  Biology of premature ageing in survivors of cancer , 2017, ESMO Open.

[20]  Russell Bonneville,et al.  Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.

[21]  L. Rigter,et al.  Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment , 2016, Gut.

[22]  S. Patrick,et al.  Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links. , 2015, DNA repair.

[23]  E. Kuipers,et al.  Somatic aberrations of mismatch repair genes as a cause of microsatellite‐unstable cancers , 2014, The Journal of pathology.

[24]  D. Dearnaley,et al.  Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma , 2013, British Journal of Cancer.

[25]  L. Friedova,et al.  Second malignancies in long-term testicular cancer survivors , 2014, International Urology and Nephrology.

[26]  M. Ladanyi,et al.  Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency , 2013, Modern Pathology.

[27]  J. Potter,et al.  Identification of Lynch syndrome among patients with colorectal cancer. , 2012, JAMA.

[28]  P. Nathan,et al.  Secondary Gastrointestinal Cancer in Childhood Cancer Survivors , 2012, Annals of Internal Medicine.

[29]  E. Kuipers,et al.  Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome , 2012, The Journal of pathology.

[30]  A. N. Bartley,et al.  Identification of Cancer Patients with Lynch Syndrome: Clinically Significant Discordances and Problems in Tissue-Based Mismatch Repair Testing , 2011, Cancer Prevention Research.

[31]  P. Okunieff,et al.  Commentary Testicular Cancer Survivorship: Research Strategies and Recommendations , 2022 .

[32]  K. Hemminki,et al.  Second cancers after testicular cancer diagnosed after 1980 in Sweden. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  E. Steyerberg,et al.  Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Schellens,et al.  Long-term platinum retention after treatment with cisplatin and oxaliplatin , 2008, BMC clinical pharmacology.

[35]  M. Louwman,et al.  Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Casparie,et al.  Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[37]  J. Olsen,et al.  Second malignancies among survivors of germ‐cell testicular cancer: A pooled analysis between 13 cancer registries , 2007, International journal of cancer.

[38]  John D Boice,et al.  Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.

[39]  X. Lin,et al.  P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. , 2001, Cancer research.

[40]  D. Sleijfer,et al.  Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer , 2000, The Lancet.

[41]  P. Hall,et al.  Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.

[42]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[43]  A. Stiggelbout,et al.  Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  P. Tothill,et al.  The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. , 1992, European journal of cancer.

[45]  E. Reed,et al.  Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. , 1992, Cancer research.

[46]  R. Lothe,et al.  Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. , 1990, British Journal of Cancer.